ATM inhibitors

Details ATM inhibitors ATM inhibitors

2006-05-23

2006-05-23

Solola, Taofiq (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S114000, C544S145000, C544S147000

Reexamination Certificate

active

07049313

ABSTRACT:
The application concerns a compound of formula I:wherein one of P and Q is O, and the other of P and Q is CH, where there is a double bond between whichever of Q and P is CH and the carbon atom bearing the R3group;Y is either O or S;R1and R2are independently hydrogen, an optionally substituted C1-7alkyl group, C3-20heterocyclyl group, or C5-20aryl group, or may together form an optionally substituted heterocyclic ring having from 4 to 8 ring atoms;R3is a phenyl or pyridyl group, attached by a first bridge group selected from —S—, —S(═O)—, —S(═O)2—, —O—, —NRN— and CRC1RC2— to an optionally substituted C5-20carboaryl group, the phenyl or pyridyl group and optionally substituted C5-20carboaryl group being optionally further linked by a second bridge group, so as to form an optionally substituted C5-7ring, the phenyl or pyridyl group being further optionally substituted.

REFERENCES:
patent: 4954518 (1990-09-01), Takano et al.
patent: 5252735 (1993-10-01), Morris
patent: 5284856 (1994-02-01), Naik et al.
patent: 5302613 (1994-04-01), Morris
patent: 5703075 (1997-12-01), Gammill et al.
patent: 5733920 (1998-03-01), Mansuri et al.
patent: 5922755 (1999-07-01), Tanaka et al.
patent: 6348311 (2002-02-01), Kastan et al.
patent: 6387640 (2002-05-01), Kastan et al.
patent: 2004/0192687 (2004-09-01), Martin et al.
patent: 0 610 519 (1994-08-01), None
patent: 0 635 268 (1995-01-01), None
patent: 0 640 339 (1995-03-01), None
patent: 0 641 566 (1995-03-01), None
patent: 0 648 492 (1995-04-01), None
patent: 0 658 343 (1995-06-01), None
patent: 1303724 (1973-01-01), None
patent: 2 302 021 (1997-01-01), None
patent: 03215-423 (1990-01-01), None
patent: WO 90/06921 (1990-06-01), None
patent: WO 91/19707 (1991-12-01), None
patent: WO 92/00290 (1992-01-01), None
patent: WO 95/29673 (1995-11-01), None
patent: WO 96/01108 (1996-01-01), None
patent: WO 97/15658 (1997-05-01), None
patent: WO 97/18323 (1997-05-01), None
patent: WO 98/55602 (1998-12-01), None
patent: WO 98/56391 (1998-12-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 01/53266 (2001-07-01), None
patent: WO 02/20500 (2002-03-01), None
patent: WO 02/20500 (2002-03-01), None
patent: WO 02/056912 (2002-07-01), None
patent: WO 03/024949 (2003-03-01), None
patent: WO 03/034997 (2003-05-01), None
patent: WO 03/035618 (2003-05-01), None
Abraham, Robert T., “Cell cycle checkpoint signaling through the ATM and ATR kinases,”Genes&Dev., 15:2177-2196 (2001).
Archer, S. et al., “Ring-Hydroxylated Analogues of Lucanthone as Antitumore Agents,”J. Med Chem., 25, 220-227 (1982).
Banin, S., et al., “Enhanced phosphorylation of p53 by ATM in response to DNA damage,”Science, 281:1674-1677 (1998).
Berge, Stephen M., et al., “Review article,”J. Pharm. Sci., 66:1, pp. 1-19 (1977).
Brown, P.O., “Integration of retroviral DNA,”Curr Top Microbiol Immunol., 157:19-48 (1990).
Daniel, Rene, et al., “Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses,”Mol. Cell Biol, 21:4, 1164-1172 (2001).
Durocher, Daniel, and Jackson, Stephen P., “DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?,”Curr Opin Cell Biol., 13:225-231 (2001).
Giroux, A., et al, “One pot biaryl synthesis via in situ boronate formation,”Tet. Lett., 38:22, 3841-3844 (1997).
Haselhorst, Dorte, et al., “Development of cell lines stably expressing human immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer,”J Gen Virol, 79:231-237 (1998).
Herzog, Karl-Heinz et al., “Requirement for ATM in ionizing radiation-induced cell death in the developing central nervous system,”Science, 280: 1089-1091 (1998).
Ishiyama, T. et al., “Synthesis of arylboronates via the palladium(0)-catalyzed cross-coupling reaction of tetra(alkoxo)diborons with aryl triflates,”Tett. Lett., 38:19, 3447-3450 (1997).
Keith, Curtis T. and Schreiber, Stuart L., “PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints,”Science, 270: 50-51 (1995).
Lavin, Martin F. and Shiloh, Yosef, “The genetic defect in ataxia-telangiectasia,”Annu. Rev. Immunol, 15:177-202 (1997).
Metcalfe, Judith A. et al., “Accelerated telomere shortening in ataxia telangiectasia,”Nature Genetics, 13:350-353 (1996).
Mlotkowska, B.L. et al., “Two-dimensional NMR studies of 2-substituted thioxanthene sulfoxides,”J. Heterocyclic Chem., 28: 731-736 (Apr.-May 1991).
Naldini, Luigi et al., “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,”Science, 272: 263-267 (1996).
Sarkaria, Jann N. et al., “Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine,”Cancer Res., 59: 4375-4382 (1999).
Savitsky, Kinneret et al., “A single ataxia telangiectasia gene with a product similar to PI-3 kinase,”Science, 268:1749-1753 (1995).
Shiloh, Yosef, “ATM and ATR: networking cellular responses to DNA damage,”Curr. Opin. Genet. Dev., 11:71-77 (2001).
Toker, Alex and Cantley, Lewis C., “Signalling through the lipid producdtsd of phosphoinositide-3-OH kinase,”Nature, 387:673-676 (1997).
Zakian, Virginia A., “ATM-related genes: What do they tell us about functions of the human gene?”Cell, 82:685-687 (1995).
Hickson, Ian, et al, Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM, Cancer Research, Dec. 15, 2004, 9152-9159, vol. 64.
Chiosis G, et al., “LY294002-geldanamycin heterodiamers as selective inhibitors of the PI3K and PI3k-related family”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 7, Apr. 9, 2001 pp. 909-913.
Hollick, J J, et al., “2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase” Bioorganic and Medicinal Chemistry Letters, vol. 13, No. 18, Sep. 15, 2003 pp. 3083-3086, XP002303369.
Bantick, J.R., et al., “Synthesis of 2-aminochromones,”J. Heterocyclic Chem., 1981, vol. 18, pp. 679-684.
Bettoni, et al., “Synthesis and absolute configuration of substituted morpholines,”Tetrahedron, 1980, vol. 36, pp. 409-415.
Boyd, J., et al., “The chemistry of the insoluble red woods,”J. Chem. Soc., 1948, pp. 174-176.
Buon, C., et al., “Synthesis of 3-substituted and 2,3-disubstituted-4H-1,4-Benzoxazines,”Tetrahedron, 2000, vol. 56, pp. 605-614.
Daniel, R., et al., “A role for DNA-PK in retroviral DNA integration,”Science, 1999, vol. 284, pp. 644-647.
Datta, A., et al., “Reformatsky reaction on aroylketene S, N-acetals: a facile route to 4-amino-6-aryl-2H-pyran-2-ones,”Synthesis, 1988, vol. 3, pp. 248-250.
Di Braccio, M., et al., “1,2-fused pyrimidines VII,”Eur. J. Med., Chem., 1995, vol. 30, No. 1, pp. 27-38.
Di Braccio, M., et al., “Pyran derivatives XIX. (Dialkylamino) substituted 1-benzopyranones and naphthopyranoes with platelet antiaggregating activity,”Farmaco, 1995, vol. 50, No. 10, pp. 703-711.
Ermili, A., et al., “Chemical and pharmacological research on pyran derivatives,” Enclosed:Chemical Abstracts, 1977, vol. 87, No. 15, p. 588 (XP-002218602). 117750g.
Gell, D., et al., “Mapping of protein-protein interactions within the DNA-dependent protein kinase complex,”Nucleic Acid Res., 1999, vol. 27, No. 17, pp. 3494-3502.
Goytisolo, et al., “The absence of DNA-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang,”Mol. Cell. Biol., 2001, vol. 21, No. 11, pp. 3642-3651.
Hartley, K. O., et al., “DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kina

Affiliated with

Also associated with

Rating

ATM inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ATM inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ATM inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3628612